JP2000229870A - Preparation of extract to be used as a substrate for obtaining therapeutic medicine treating human diseases caused by viruses - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a substrate extract that is useful as a medicine for treating human diseases caused by viruses, for example, influenza or common cold, by cutting a mixture of fruits and the like of a tree (Sambucus nigara L.) into tiny pieces, extracting them with boiled water and filtering the extract by a specific method. SOLUTION: (A) An even mixture of 66-72 wt.% of the fruits of the elder tree, 11-14 wt.% of the barks of branches, and 17-20 wt.% of the leaves is cut at their wood parts into tiny pieces of <=1 cm size. (B) 70-90 grams, preferably 15-85 grams of the component A per liter of the component B are added to boiled water and heated, preferably for 45 minutes to decoct the component A and the heating is stopped. Then, decoction product is subjected to the first decantation, the second filtration through a sieve to remove solid pieces to obtain the substrate extract. This extract is useful as a substrate material for medicines, for example, nasal and throat congestion, non-bacterial throat inflammation, or laryngitis, and the diseases caused by viruses that bear ribonucleic acid as an genetic material. This extract is used as a substrate material for medicines, for example, tablets, powder and the like.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

The object of the present invention is to provide a method for preparing an extract used as a base for obtaining a medicament required for the treatment of a human disease of viral origin, a human disease of viral origin (eg influenza, Such as colds, pharyngitis or non-bacterial throat inflammation), preparations and syrups used as medicaments necessary for the treatment of such diseases, which are generally caused by viruses having ribonucleic acid as genetic material Mold, the extract obtained by said method, as well as the product obtained from such an extract, which provides significant therapeutic properties.

[0002]

BACKGROUND OF THE INVENTION Traditionally, plants have provided therapeutics for numerous human diseases. That is, many of them are regarded as drugs, despite the fact that the principle of activity and / or the process thereof is unknown and their chemical active principle is often unknown. Elderberry (Sambucus nigra)
L.) stands out among the vast number of medicinal plants described in phytotherapy books. That is, the decoction of elderflower is useful for treating cold, bronchial fever and hay fever (R. Mab
ey et al., A new era for herbs, Everest, Leon ed., 198
8). Elder-based ointments, on the other hand, are useful for treating frostbite and skin abrasions. Elderberry decoction has typically been used to treat cough and cold (P. Font Quer, Medicinal Plants, The renewed di
oscorides, edited by Labor SA, 11th edition, Barcelona, 1988; R.M.
abey et al., A new era for herbs, Everest, Leon, 198
8).

[0003]

The mixture of plant drugs is
Plants are very complicated because they are living creatures and contain secondary metabolites. In terms of phytotherapy, in general,
Different mixtures of plants, especially elderberry, at different sites yield different mixtures. That is, elderberry is rich in vitamin C, organic acids and bioflavonoids;
Its leaves are rich in various vitamins, tannins, resins and cianogenic type glucosides; and its flowers are rich in terpenes and flavonoids (R. Mabey et al., A new era for herbs, Eve
rest, Leon, 1988). In addition, elderberry contains a variety of functional proteins with therapeutic activity, especially certain lectins and proteins that inactivate the ribosome.

[0004] In particular, lectins are fructose-binding proteins and can therefore interfere with the identification process of cells, viruses and bacteria. The lectin known to be present in elderberry is SNA (Sambucus ni
gra agglutinin) I and SNAII, and SNA in fruits
III. SNA I, like SNA II, binds to the intestinal mucosa, and some of these processes require receptor-mediated endocytosis (A. Pusztai et al., Digestio
n, Volume 46, Supplement 2, pp. 308-316, 1990) and is absorbed into the blood through the intestinal mucosa (A. Pusztai et al., Lectin R).
eviews, Vol. 1, 1-15, 1991). SNA III contained in elderberry (Van Damme et al., Eur. J. Bioche
m., 237, 505-513, 1996, now SNA IV
No known studies have been performed on binding and absorption by the intestinal mucosa.

[0005] Ribosome inactivator proteins are inhibitors of protein biosynthesis (Gasperi-Campani et al., B
iochem. J., 186, 439-441, 1980; Gasperi-Camp
ani et al., J. Nat. Prod., 48, 446-454, 1985; Fer.
Reras et al., Cell. Mol. Biol., 35, 89-95, 1989;
Merino et al., J. Exp. Bot., 41, 67-70, 1990; Gir
bes et al., Cell. Mol. Biol., 38, 803-812, 1992;
Citores et al., Cel. Mol. Biol., 39, 885-995, 199.
3; Stirpe et al., Bio / technol, Vol. 10, pp. 405-412, 199.
2; Citores et al., FEBS Lett, Vol. 329, pp. 59-62, 199
3). Such a protein can be one polypeptide chain (type 1) or two polypeptide chains (type 2)
Alternatively, it may be formed by four polypeptide chains (type 4) (Citores et al., FEBS Lett, 329, 59-62,
1993).

The ribosome-inactivating protein formed by one polypeptide chain has N-glucosidase activity on ribosomal nucleic acids (A chain) and one lectin (B chain) (Stirpe et al., Bio / technol. Volume 10,
405-412, 1992), the B chain usually recognizes galactose residues and derivatives thereof. The four-chain protein consists of AB dimers, each of which is similar to type 2 molecules (Citores et al., FEBS Lett, 329).
Vol. 59-62, 1993). These proteins (A and B chains) have a molecular weight of 20,000-34,000. The A chain
Inhibits ribosome action by a catalytic process of ribonucleic acid inactivation (Jimenez y Vazques, Ann. Rev. Mic
robiol., Vol. 39, pp. 649-672, 1985; Roberts & Selitr
ennikoff, Biosc. Rep., 6, 19-29, 1986; Stir
pe & Barbieri, FEBS Lett, Vol. 195, pp. 1-8, 1986;
Stirpe & col., Bio / technol, Vol. 10, pp. 405-412; Cit
ores & col., FEBS Lett, Vol. 329, pp. 59-62, 1993; Gi
rbes et al., J. Biol. Chem., 268, 18195-18199, 19
93; Girbes et al., Plant. Mol. Biol., Vol. 22, 1181-1186.
1993).

[0007] Three RIP models, together with two nigrin chains, have been identified and published in elderberry: b nigrin in bark (Girbes et al., Plant. Mol. Biol., No. 22).
Vol. 1181-1186, 1993), f-nigrin in fruit (Girbe
s et al., Biochem. J., Vol. 315, pp. 343-344, 1996; Girbes.
, J. Exp. Bot. 47: 1577-1785, 1996), and snigrin in seeds (Citores et al., J. Exp. Bot.,
45, 513-516, 1994). These are also all
The B chain shows some activity of D-galactose-specific lectins.

Recently, the SNA lectin has been shown as a true RIP (Van Damme et al., Eur. J. Biochem., 235, 128-
137, 1996). This explains the relative toxicity of such proteins in intestinal binding and absorption studies (A. Pusztai et al., Lectin Reviews, Vol. 1, 1-15.
1991). Recent experimental data (Batelli et al., Arch. Tox
According to icol., 1996), nigrin is a toxic substance in Swiss rats weighing 30 g (the LD50 (mean lethal dose) for 15 days is 12 mg / kg body weight).

Finally, Sambucol (W. Elliman, Hadassah)
Magazine, pp. 40-41, December, 1994) describes a complex preparation containing an elderberry extract. It contains extracts of elderberry and currant, among other ingredients. In addition, Sambuco
l contains the native non-denatured protein of elderberry. The source of its activity, as already described, is a non-denatured natural protein with lectin action which is contained in the preparation and absorbed by the blood upon ingestion. This protein exerts antiviral effects as indicated in available sources (W. Elliman, Hadassah Mag
azine, pp. 40-41, December, 1984).

The above preparation has anti-influenza activity,
It is generally stated to exhibit antiviral activity. Lectins and RIP have certain toxicity. The use of preparations containing non-denatured elder proteins involves several risks that must be considered before administration to humans (A. Pusztai et al.,
Lectin Reviews, Vol. 1, 1-15, 1991).

In fact, it has been known for some years that drinking untreated or poorly treated elder juice may cause nausea and vomiting to a degree depending on the actual degree of untreatment. (Bergman, Flussiges Obst., Chapter
46, 8, 1979; Kuglmann, Lebensm Rdsch., 75
390, 1979). It is known that fruits containing toxic bioactive proteins may be the source of these effects. Such proteins include f-nigrin in pulp (Girbes et al., Biochem. J., Vol. 315, 34
3-344, 1996; Girbes et al., J. Exp. Bot., Vol. 47, 157.
7-1785, 1996), s nigrins in seeds (Citores et al.,
J. Exp. Bot., 45, 513-516, 1994), S in pulp
NA IV lectin (Mach et al., Biochem. J., vol. 278, 667-6
71, 1991).

On the other hand, lectins, like elderberry RIP, are very immunological (Girbes et al., J. Exp. Bot.
47, 1577-1785, 1996). Thus, when a lectin is ingested and absorbed into the plasma, neutralizing antibodies are generated that interfere with the potential effects of such proteins. In order to make efficient use of the therapeutic properties of the different components of the elderberry, and to properly compensate for some of the deficiencies found in preparations obtained from the elderberry, the pharmaceuticals needed to treat human diseases of viral origin The development of a process for the preparation of the extract as a base required for the production has been carried out: the extract obtained by the method described above, as well as such a product obtained from such an extract, for the purposes of the present invention It has certain remarkable therapeutic properties.

[0013]

SUMMARY OF THE INVENTION The present invention relates to a process for the preparation of an extract as a base for use in obtaining a medicament required for the treatment of human diseases of viral origin and to the products obtained by said process. , Elderberry (Sambucus nigra)
Heat-denatured complex water-soluble substances obtained from the mature fruits, bark and leaves of corn, combining their respective therapeutic properties in a synergistic manner, resulting in the potential of non-denatured proteins of elderberry It consists of a complex heat-denatured water-soluble substance that avoids toxic effects.

[0014] As a base used to obtain the medicinal products necessary for the treatment of human diseases of viral origin in order to obtain the final product, a method for the preparation of extracts from mature elders, bark and leaves of elderberry is For the purposes of the present invention, it is based on the successive application of the different steps of the method. In that case,
Factors such as the components required, the amount used and the time spent in the different steps, as well as other manufacturing factors, are very important.

Further, for the purposes of the present invention, the method comprises the steps of: obtaining a homogeneous mixture of elderberry, bark of the branches and leaves, the proportions of which are in the following weight percentages: One, elderberry 66-72% elderberry bark 11-14% elderberry leaf 17-20%; chopping the woody material obtained by the above process to obtain small pieces of 1 cm or less; obtained by said process Adding the homogeneous mixture to boiling water at 70-90 grams per liter, more preferably 75-85 grams of the mixture; decocting the mixture, preferably by heating for 45 minutes, and stopping the treatment after that time Removing all solids from the extract produced by said process; this step comprises:
A second step of filtering, preferably through a sieve,
Including the sub-steps.

The elder nuts used for the preparation of the mixture in the first step should be soft mature fruits, preferably of dark red wine color. The elder branches used for the bark that must be included in the mixture of the first step should preferably be young annual branches. Similarly, the elder leaves used for the preparation of the mixture should preferably be grown or mature leaves, preferably with a maximum axis of 5 to 12 cm, preferably 7 to 10 cm.

Furthermore, each component of the product elderberry involved in the process object of the present invention can be fresh or at a temperature below -15 ° C., preferably between -15 ° C. and -30 ° C. Can be frozen.

Optionally, the elder nuts, leaves and bark comprise:
It can be decocted individually at the same weight / volume ratio and then mixed with the individual extracts to obtain a complete extract.

The final extract obtained by the solids removal step is obtained by different processing steps to prepare said substance such as a water-soluble decoction or syrup, pill or tablet, powder or liquid or solid caramel. Can be processed.

In order to prepare a product from the complete extract as a water-soluble substance or syrup, one volume of the complete extract obtained by the solids removal step is preferably mixed with one part to obtain a homogeneous product. Must be mixed with a volume of pure honey. This homogeneous mixture is preferably placed in an opaque or topaz container to avoid light that alters the nature of the chemical components of the preparation.

To prepare the product from the whole extract as a solid or liquid caramel, one part by volume of said extract is preferably one part by volume of honey or hydrolyzed caramelized cereals. Must be mixed with.

Optionally, the extract obtained by the solids removal step, together with other plant extracts, in combination with other substances and products, does not substantially alter the basic therapeutic properties provided by the elderberry component A preparation can be obtained. Such plants include the following plants: Filipendula ulmari
a), Primula veris, Boragoofficinalis, Hyssopus officinalis, Echinacea angustifolia, Eupatorium perfoliatum, Eupatorium Eupatorium cannabium), Achillea millefolium, Mentha piperita, Mentha spicat
a), Eucalyptus globulus, Thymus vulgaris, Salvia offici
nalis), Rosmanus officinalis, Tuessilago farfara, Hypericum perforatum (Hypericum perforatum), and Melissa officinalis.

In order to better understand the objects of the present invention, the method used to prepare the extract as a base for obtaining a medicament required for the treatment of human diseases of viral origin, which comprises: The preferred practical application of (which is the object of the present invention), as well as the tests performed on the sick according to the results obtained, which do not limit the scope, are described.

The practical application of the method used to prepare the extract as a base to obtain a medicament required for the treatment of human diseases of viral origin is the influenza, cold, nasal and pharyngeal congestion and non-bacterial Preparations used as drugs necessary for the treatment of human diseases of viral origin, such as sexual throat inflammation or pain, generally caused by viruses having ribonucleic acid (RNA) as genetic material Beginning by selecting the components of the elderberry that must be used in the application of the method, such as nuts, bark and leaves of the branches, similar to objects and syrups.

Thus, the elderberry used in the preparation of the mixture is a soft, mature, dark red wine color. The elder branches bark used in the mixture should preferably be young branches up to 1 year old. Elderberry branches tend to be stiff, and therefore make the bark preparation process more difficult. Similarly,
The elder leaves used for the preparation of the mixture are preferably grown or mature leaves, the largest axis of which should be 7-10 cm.

For practical applications of the present invention, 55 grams of dark red wine-colored elderberry (fresh or frozen at -20 ° C.), 10 grams of annual bark (not yet) Processed or frozen at -20 ° C) and 15 grams of annual mature, elderberry leaves whose maximum axis is 7-10 cm (frozen or untreated at -20 ° C) are mixed .

Thereafter, the mixture of woody materials is chopped,
Make small pieces of 1cm or less. The mixture is then added to one liter of boiling water and kept boiling for 45 minutes.

This boiling treatment is once terminated, and a solid substance is removed by a decantation treatment first, followed by a filtration using a sieve.

The complete extract obtained by the present method can be subjected to different treatments such as water-soluble decoction or syrup, pills or tablets, powder or solid or liquid caramel.

To prepare the product from the final extract as a water-soluble substance or syrup, one volume of the complete extract obtained by the solids removal step is mixed with one volume of pure honey. If necessary, one part by volume of the concentrated solution of the extract and one part by volume of the hydrolyzed serial can also be mixed.

[0031]

DETAILED DESCRIPTION OF THE INVENTION The therapeutic efficiency of the complete extract obtained from elderberry by the described method is not only non-bacterial sore throat, but also of viral origin such as influenza, cold, nasal and pharyngeal congestion. Antibodies based on the results obtained by a series of tests (described below) performed when successfully combating some of the human diseases as well as in the other applications described above and performed on patients affected by the disease. Has viral therapeutic activity. In such tests, in the case of influenza and cold, the etiology is RN
Viruses of type A (ribonucleic acid): influenza viruses of types A, B and C (DP Stites & AL Ter
r, Basic & Clinical Immunology, pp. 646-656, Lange M
edical Book, Appleton & Lange, Norwalk, Conneticu
t, USA, 1987), and rhinovirus in the case of cold (DJ Jeffries & E. De Clerk, Antiviral chemoth)
erapy, pp. 321-355, John Wiley & Sons, New York, US
A, 1995). The tests performed were as follows.

Test 1-Application of Syrup-like Extract to Case No. 1 Highly robust with no early stage influenza (first 24 to 48 hours) characterized by headache, nasal congestion and fever A 44-year-old man was given the extract. The patient was given a spoonful of syrup (9 ml) every 6 hours. After 24 hours of treatment, the flu symptoms had substantially improved and disappeared after 24 hours (full recovery).

Trial 2-Application of Syrup Extract to Case No. 2 For early stage (first 24 to 48 hours) influenza characterized by headache, nasal congestion, fever and severe pharyngitis painful on eating. A 31-year-old woman who had no chronic disease was given the extract. The patient was given a spoonful of syrup (9 ml) every 6 hours. After 24 hours of treatment,
The symptoms of the flu improved substantially and disappeared completely after 24 hours (full recovery).

Trial 3-Application of Syrup Extract to Case No. 3 A highly robust 44-year-old flu suffering from influenza in the early stages (first 24-48 hours) characterized by headache and fever without chronic illness Men were given the extract. The patient was given a spoonful of syrup (9 ml) every 6 hours. twenty four
After hours of treatment, the symptoms disappeared (full recovery).

Test 4-Application of Syrup-like Extract to Case No. 4 A 9-year-old, normal developing child with severe nasal congestion, cold sore throat in the early stages (first 24 hours), without chronic illness The girl was fed the extract. The patient was given a teaspoon of syrup (2 ml) every 6 hours. After 24 hours of treatment, the symptoms improved substantially and disappeared completely after 48 hours (complete recovery).

Test 5-Application of Syrup to Case No. 5 A 43-year-old man with severe cold nasal congestion and severe pharyngitis without chronic illness was ingested with the extract. . Three days later, give the patient a spoonful of syrup (9m
l) was administered every 6 hours. After 24 hours of treatment, the symptoms completely disappeared (complete recovery).

Test 6-Application of Syrup to Case No. 6 A highly robust 36-year-old man suffering from nasal congestion and severe cold with severe pharyngitis without chronic illness was allowed to ingest the extract. Was. Three days later, the patient received one teaspoon of syrup (2 ml) every 8 hours. After 24 hours of treatment, the patient's symptoms improved substantially, but the cold did not resolve (partial recovery). Treatment continued for two days. The lack of improvement in cold symptoms may indicate that the dose of the syrup was insufficient.

Test 7-Application of Syrup-like Extract to Case No. 7 Influenza in the early stages (first 24 to 48 hours) characterized by headache, nasal congestion and some fever and pharyngitis with chronic diseases Not a highly robust 38-year-old man,
The extract was applied. Give the patient a spoonful of syrup (2m
l) was administered every 6 hours. After 24 hours of treatment, the flu symptoms improved substantially and disappeared completely after 24 hours (complete recovery).

Test 8-Application of Syrup-like Extract to Case No. 8 A 41-year-old woman with pharyngitis, with influenza in the early stages (first 24 hours), without chronic illness, ingested the extract. Was. Give the patient a spoonful of syrup (9m
l) was administered every 6 hours. After 24 hours of treatment, the flu symptoms had improved substantially and disappeared completely after 24 hours (full recovery).

Test 9-Application of Syrup-like Extract to Case No. 9 A moderately robust 24-year-old man with severe pharyngitis and no chronic disease was ingested with the extract. 1 tsp for patient
A serving of syrup (2 ml) was administered every 6 hours. 24-48
After time treatment, the symptoms disappeared completely (full recovery).

Test 10-Application of Syrup Extract to Case No. 10 Moderately robust without chronic illness with influenza in the early stages (first 24 to 48 hours) characterized by headache, nasal congestion and fever A 33-year-old man was given the extract. The patient was given a teaspoon of syrup (2 ml) every 6 hours. After 24 hours of treatment, the flu symptoms had substantially improved and disappeared after 24 hours (full recovery).

Test 11-Application of Syrup Extract to Case No. 11 Highly robust, without chronic illness, with influenza in the early stages (first 24 to 48 hours) characterized by headache, nasal congestion and fever A 42-year-old woman was given the extract. The patient was given a teaspoon of syrup (2 ml) every 6 hours. After 24 hours of treatment, the flu symptoms had substantially improved and disappeared after 24 hours (full recovery).
Bronchitis developed and did not resolve during the treatment period due to the symptoms.

Test 12-Application of Syrup-like Extract to Case No. 12 Extracted into a normal developing 8-year-old child with severe cold with pharyngitis in the early stages (first 24 hours) and without chronic illness They were ingested. Give the patient 1 teaspoon of syrup (2
ml) was administered every 6 hours. After 24 hours of treatment, the flu symptoms had substantially improved and disappeared after 24 hours (full recovery).

Test 13-Application of syrupy extract to case number 13 Early stage (first 24 hours) with fever of 37 ° C. and chronic illness with nasal and pharyngeal congestion but without gastric disorders A moderately robust 43-year-old man was fed the extract. The patient was given a spoonful of syrup (9 ml) every 6 hours. After 24 hours of treatment, the fever disappeared and the patient improved substantially. Treatment lasted 1.5 days, but seemed too short. After 3 days, the treatment was resumed and continued for 24 hours, and the symptoms completely disappeared (complete recovery).

Test 14-Application of Extract Syrup to Case No. 14 Normally developing 7-year-old with cold nasal and pharyngeal congestion in the early stages (first 24 hours) with fever of 37 ° C. without chronic disease Children received syrup. The patient received one teaspoon of syrup (2 ml) every 6 hours (total volume 6 ml). After 24 hours of treatment, the fever and symptoms disappeared completely (full recovery).

Test 15-Application of extract syrup to case no. 15 8.5 of normal development without chronic illness with severe cough in the early stages (first 24 hours) and cold with a lot of mucus
Aged children were given syrup. The patient was given a teaspoon of syrup (2 ml) every 6 hours (total volume 6 m)
l). After 24 hours of treatment, the symptoms completely disappeared (complete recovery).

Study 16-Application of extract syrup to case number 16 Severe headache, nasal congestion and fever, and early stage (first 24-48 hours) severe influenza characterized by severe pharyngitis and bronchitis A highly robust 45-year-old man without illness and chronic illness was given syrup.
The patient was given a spoonful of syrup (9 ml) every 6 hours. After 48 hours of treatment, the flu symptoms disappeared, and after 72 hours, pharyngitis disappeared. Treatment continued for only three days. The bronchitis disappeared 4 days after the start of the treatment.

Test 17-Application of Extract Syrup to Case No. 17 Normal development with early stage (first 24 hours) of congestion, sore throat (great and painful pain) and mild bronchitis without chronic disease Of the 7.5-year-old children took the syrup. Give the patient 8 teaspoonfuls of syrup (2 ml)
The dose was administered every hour. After 48 hours of treatment, the sore throat and congestion disappeared, but bronchitis persisted for more than 3 days. Treatment continued for two days.

Test 18-Application of Extract Syrup to Case No. 18 A 12.5-year-old girl with a common cold and no chronic disease was fed a syrup. The patient was given a spoonful of syrup (2 ml) every 6 hours. After 48 hours of treatment, the cold had disappeared. Treatment continued for two days.

Study 19-Application of Extract Syrup to Case No. 19 A highly robust 45-year-old man with severe influenza of the early stage (first 24 hours) with severe sore throat and without chronic illness Was ingested syrup. The patient was given a spoonful of syrup (9 ml) every 6 hours. After 48 hours of treatment, the symptoms disappeared. Pharyngitis disappeared within 4 days. Treatment continued for two days.

Test 20-Application of extract syrup to case number 20 Early stage characterized by headache and fever (first 48 hours)
A 50-year-old woman with severe influenza and severe cough and congestion was given syrup. The patient was given a teaspoon of syrup (9 ml) every 6 hours. After 24 hours of treatment, the symptoms disappeared (full recovery).

Test 21-Application of Extract Syrup to Case No. 21 Suffering from early stage influenza,
A syrup was given to a normal, 26-year-old man with normal physical development without congestion, moderate fever and headache and no chronic illness except for stomach effects due to ulcer status. The patient was given a spoonful of syrup (9 ml) every 6 hours. After 24 hours of treatment, all symptoms had virtually disappeared. Treatment consisted of three doses. Slight gastric pain was noted immediately after treatment was stopped.

Test 22-Application of Extract Syrup to Case No. 22 A 41-year-old man with very severe influenza and colds and no chronic illness was ingested syrup.
The patient was given a spoonful of syrup (9 ml) every 4 hours. After 48 hours of treatment, the flu symptoms disappeared, but the cold symptoms did not. Treatment started 3 days after the appearance of symptoms and continued for 4 days. After treatment, the cold persisted.

[0054]

The complete extract obtained from the elderberry by the above method is not only a non-bacterial sore throat, but also a variety of diseases and diseases of viral origin such as influenza, cold, nasal and pharyngeal congestion. It has antiviral therapeutic activity that is manifested when administered to humans to fight.

Further, an extract as a base for obtaining a drug required for the treatment of a human disease of viral origin, which is obtained by the method included in the present invention, comprises A
Human diseases such as hepatitis C, hepatitis C, hepatitis D and E, etiology caused by Epstein-Barr virus, and human immunodeficiency virus type 1 (HIV-1)
Or used for AIDS caused by type 2 (HIV-2).

Having fully described the features of the invention and the method for practicing the invention, the inventors believe that the features of the invention may be modified without substantially altering the features of the invention as set forth in the following claims. It must only be added that variations in material and composition are possible.

 ──────────────────────────────────────────────────続 き Continuation of the front page (72) Inventors Hilves Juan, Thomas A-47014 Valladolid. 127, Caie Milliam Brasco, F-term (reference) 4C088 AB12 AB26 AB38 AB51 AB57 AC04 AC05 AC06 AD10 BA03 BA08 CA01 CA02 CA05 MA02 MA07 MA08 MA17 MA23 MA34 MA35 MA43 NA14 ZA34 ZA36 ZA59 ZA75 ZB11 ZB33 ZC55

Claims (14)

[Claims] 1. A method used for the preparation of a base extract intended to obtain a medicament for treating a human disease of viral origin, said preparation comprising influenza, cold, nasal Syrups used as medicaments for the treatment of human diseases of viral origin, such as pharyngeal congestion and non-bacterial throat inflammation or pharyngitis, and diseases caused by viruses with ribonucleic acid (RNA) as genetic material, There are pills, tablets, powders, caramels and the like, the method comprising the steps of: obtaining a homogeneous mixture of elderberry, bark of the branches and leaves, the proportions of which are: Elderberry 66-72% Elderberry branch bark 11-14% Elderberry leaf 17-20%; small pieces of 1 cm or less were obtained. Chopping the woody substance of the homogeneous mixture obtained by said step; adding the homogeneous mixture obtained by said step to boiling water at a mixture of 70-90 grams, more preferably 75-85 grams per liter; Decoct the mixture obtained by the above step, preferably by heating for 45 minutes,
Stopping the heat treatment after that time; removing solids from the extract obtained by said step, comprising a first decantation treatment and a filtration treatment using a second sieve. 2. A method for preparing a substrate extract used for obtaining a medicament for treating a human disease of viral origin according to claim 1, wherein the method is used for obtaining the homogeneous mixture. I.e. the elderberry in the first step must be soft ripe fruit, preferably of dark red wine color, which is used to obtain said homogeneous mixture, i.e. the elder branches in the first step Should be young branches, preferably up to one year, and the elder leaves used to obtain said homogeneous mixture in the first step are preferably grown or mature leaves, preferably having a maximum axis of 5 ~ 12cm, preferably 7 ~ 10
cm. 3. A method for preparing a substrate extract used for obtaining a medicament for treating a human disease of viral origin according to claim 1 or 2, wherein the product involved in said method is prepared. It is characterized in that the components of the elderberry can be in a raw state or can be frozen at a temperature below -15C, preferably between -15C and -30C. 4. A method for preparing a base extract used for obtaining a medicament for treating a human disease of viral origin according to any one of claims 1 to 3, wherein the extract comprises elderberry. , Individual decoctions of leaves and bark can be prepared in the same weight / volume ratio, and then to obtain a complete extract,
It is characterized in that it can be combined with individual extracts. 5. An extract obtained by the method according to claim 1. 6. The extract according to claim 5, characterized in that the extract can be subjected to different processing steps in order to obtain a medicament such as an aqueous solution or syrup, pill or tablet, powder or liquid or solid caramel. Extract. 7. A composition comprising 1 part by volume of said extract and 1 part by volume of a homogeneous solution of pure honey,
A pharmaceutical product obtained from the extract according to claim 5. 8. The extract obtained according to claim 5, characterized in that it preferably consists of 1 part by volume of a concentrate of the extract and 1 part by volume of a homogeneous solution of hydrolyzed serial. Medicines. 9. A medicament obtained from the extract according to claim 5, characterized in that it is kept in an opaque or topaz container. 10. A composition comprising 1 part by volume of said extract and preferably 1 part by volume of a caramelized mixture of nectar or hydrolyzed caramelized carial.
A pharmaceutical product obtained from the extract according to claim 5. 11. A combination comprising the extract and an extract of at least another plant,
A pharmaceutical product obtained from the extract according to claim 5,
Preferably, the plant is one of the oilseed plants (Fil)
ipendula ulmaria), Chiba nanoculin cherry (Primula veris), Borago officinalis,
Willow mint (Hyssopus official)
is), Echinacea angustifolia (Echi
nucea angustifolia), Eupatorium perfoliatum (Euypatorium pe)
rfoliatum), Yupatorium cannadium (Eu)
patricium cannabium), Achillea millefolium (Achillea millefoliu)
m), Mentha piperit
a), Mentha spicat (Mentha spicat)
a), Yukarijutsu globu
rus), Thymus vulg
aris), Salvia (Salviaofficina)
lis), Mannenrou (Rosmarinus of)
ficinalis, coltsfoot (Tussila)
go farfara, Hypericum perforatum (Hy)
percisum) and Melissa officinalis (Melissa officin)
alis). 12. A medicament obtained from the extract obtained by the method according to claim 1, which is also applied to the treatment of hepatitis A, C, D and E. 13. The human immunodeficiency virus type 1 (HI)
Pharmaceutical obtained from the extract obtained by the method according to claim 1, characterized in that it is also applied to the treatment of immunodeficiency syndrome (AIDS) caused by V-1) or type 2 (HIV-2). . 14. A medicament obtained from the extract obtained by the method according to claim 1, characterized in that it also applies to the etiology caused by the Epstein-Barr virus.